Symdeko FDA Approval History
FDA Approved: Yes (First approved February 12, 2018)
Brand name: Symdeko
Generic name: ivacaftor/tezacaftor and ivacaftor
Dosage form: Tablets
Company: Vertex Pharmaceuticals Incorporated
Treatment for: Cystic Fibrosis
Symdeko (ivacaftor/tezacaftor tablets and ivacaftor tablets) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and CFTR corrector combination for the treatment of cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the CFTR) gene that is responsive to Symdeko.
Development Timeline for Symdeko
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.